Dual Targeting With an HDAC 6 Inhibitor and Bortezomib in Lymphoma
Jennifer E. Amengual, MD, discusses the study she presented at the 2013 American Society of Hematology (ASH) Annual Meeting. The trial analyzed dual targeting with the HDAC inhibitor ACY-1215 and bortezomib in preclinical models of lymphoma.
Clinical Pearls
Jennifer E. Amengual, MD, Center for Lymphoid Malignancies, Columbia University Medical Center, discusses the study she presented at the 2013 American Society of Hematology (ASH) Annual Meeting. The trial analyzed dual targeting with the HDAC inhibitor ACY-1215 and bortezomib in preclinical models of lymphoma.
- Class IIb HDAC 6 inhibitors work differently than class I and class IIa inhibitors
- Inhibition of HDAC 6 with ACY-1215 leads to accumulation of misfolded proteins within the cell and ultimately apoptosis
- Researchers believe that this dual targeting of protein degradation pathways could be a rational approach to treat lymphoma
<<<
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
